用于治疗骨质疏松症的控释药物递送进展。
Advances in Controlled Drug Delivery for Treatment of Osteoporosis.
作者信息
Asafo-Adjei T A, Chen A J, Najarzadeh A, Puleo D A
机构信息
Department of Biomedical Engineering, University of Kentucky, 522A Robotics and Manufacturing Building, Lexington, KY, 40506-0108, USA.
出版信息
Curr Osteoporos Rep. 2016 Oct;14(5):226-38. doi: 10.1007/s11914-016-0321-4.
Osteoporosis, which is characterized by resorption of bone exceeding formation, remains a significant human health concern, and the impact of this condition will only increase with the "graying" of the worldwide population. This review focuses on current and emerging approaches for delivering therapeutic agents to restore bone remodeling homeostasis. Well-known antiresorptive and anabolic agents, such as estrogen, estrogen analogs, bisphosphonates, calcitonin, and parathyroid hormone, along with newer modulators and antibodies, are primarily administered orally, intravenously, or subcutaneously. Although these treatments can be effective, continuing problems include patient noncompliance and adverse systemic or remote-site effects. Controlled drug delivery via polymeric, targeted, and active release systems extends drug half-life by shielding against premature degradation and improves bioavailability while also providing prolonged, sustained, or intermittent release at therapeutic doses to more effectively treat osteoporosis and associated fracture risk.
骨质疏松症以骨吸收超过骨形成为特征，仍然是一个重大的人类健康问题，而且随着全球人口的“老龄化”，这种疾病的影响只会增加。本综述重点关注用于递送治疗药物以恢复骨重塑稳态的现有和新兴方法。著名的抗吸收和促合成药物，如雌激素、雌激素类似物、双膦酸盐、降钙素和甲状旁腺激素，以及更新的调节剂和抗体，主要通过口服、静脉注射或皮下注射给药。尽管这些治疗可能有效，但持续存在的问题包括患者依从性差以及全身性或远处部位的不良反应。通过聚合物、靶向和主动释放系统进行的可控药物递送通过防止药物过早降解来延长药物半衰期，并提高生物利用度，同时还以治疗剂量提供延长、持续或间歇性释放，以更有效地治疗骨质疏松症及相关骨折风险。
Zotero 插件